Chronic Condition Management

New research finds direct-acting antivirals can be given safely to those on liver transplant waitlist.

A lack of improvement in HbA1c compared with patients who monitor glucose indicates that monitoring should not be routine, according to new research.

Good, long-term control of HbA1c may help prevent depressive symptoms in elderly with type 2 diabetes, according to a new study.

Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.

A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.

Sticking with a prevention program for one year increased the likelihood of success

A Los Angeles-based program eliminated 14,000 unnecessary visits to specialty care professionals and reduced wait times for patients in need.

A shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.

New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.

Improvements in glycemic control from combined diet and physical activity intervention drove down use of routine medications, according to new study.

Study: Achieving stringent HbA1c goals within 6 months of initiating metformin predicted decreased risk.

The introduction of direct-acting antiviral agents has transformed hepatitis C care among veterans.

Multiple oral direct-acting antiviral agents show great promise in treating the vast majority of hepatitis C patients.

Monitoring of arterial stiffness could be a potential target for prediction of renal decline in younger type 2 diabetes patients.

Targeting all eligible patients would be cost-effective, but cost might be reduced by focusing on certain patient subgroups.

Early data shows promise in “real-world” effectiveness.

Physicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.

Previous estimates based on cause of death on death certificates underestimated the problem.

A genetic predisposition to having increased abdominal fat increased risk for diabetes and heart disease, according to a new study.

All-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.

Researchers say theirs is first national study with a large population to examine possible link.

New study indicates vulnerable subgroups of diabetes patients did experience adverse outcomes due to change in health insurance coverage.

New definition opens the door to full Medicare coverage for CGMs.

A new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant.

Direct-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author.